Skip to main content
OpenTrials
Completed

NCT Number: NCT01985230

ReActiv8 for Chronic Low Back Pain (PMCF)

The purpose of this Clinical Study is to investigate the effect of electrical stimulation for chronic low back pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pain Medicine of South Australia, Adelaide, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years, ≤65 years
  • Chronic Low Back Pain with a first occurrence >90 days prior to enrolment, and the last relatively pain-free time >90 days prior to enrolment.
  • Continuing low back pain despite >90 days of medical management
  • Oswestry Disability Index score ≥25% and ≤60% at the time of enrolment
  • Able to understand and sign the Informed Consent form.
  • Ability to comply with the instructions for use and to operate the ReActiv8, and to comply with this Clinical Investigation Plan.
  • Suitable for ReActiv8 surgery as determined by the implanting physician prior to inclusion.
  • Prior week average Low Back Pain NRS of ≥6.0 and ≤9.0 on a 11 point NRS scale (0-10) at the Baseline Visit

Exclusion criteria

  • BMI > 35
  • Back Pain characteristics:
  • Any surgical correction procedure for scoliosis at any time, or a current clinical diagnosis of scoliosis.
  • Lumbar spine stenosis, as defined by an anterior-posterior diameter of the spinal canal of <10mm in subjects with lower extremity pain
  • Neurological deficit possibly associated with the back pain (e.g. foot drop).
  • Back pain due to pelvic or visceral reasons (e.g.: endometriosis or fibroids) or infection (e.g.: post herpetic neuralgia).
  • Back pain due to inflammation or damage to the spinal cord or adjacent structures (e.g. arachnoiditis or syringomyelia)
  • Any current indication for back surgery according to local institutional guidelines, or has indication for back surgery but cannot undergo surgery for other reasons.
  • Leg pain described as being worse than back pain, or radiculopathy (neuropathic pain) below the knee.
  • Source of pain is the sacroiliac joint as determined by the Investigator.
  • Drug use
  • Surgical and other procedures exclusions
  • Any prior diagnosis of lumbar vertebral compression fracture, lumbar pars fracture, or lumbar annular tear with disc protrusion
  • Planned surgery.
  • Co-morbid chronic pain conditions
  • Other clinical conditions
  • Psycho-social exclusions
  • Protocol Compliance Exclusions
  • General exclusions

Treatment and study plan

ReActiv8 Implantable Stimulation System implanted and activated.

Device

Primary outcomes

  1. 11 Point Numerical Rating Scale (NRS) for Low Back Pain

    Time frame: 90 days

  2. Number of subjects with Adverse Events

    Time frame: 90 days, 12 months

Secondary outcomes

  1. Oswestry Disability Index

    Time frame: 90 days

Other outcomes

  1. Subject Global Impression of Change

    Time frame: 90 days

Sponsors and collaborators

Lead sponsor

Mainstay Medical

Industry

Registry information

Official study title

Investigation of the ReActiv8 Implantable Stimulation System for Chronic Low Back Pain

Acronym: ReActiv8-A

Important dates

Study start
2014
Primary completion
2016
Study completion
2024
First posted
Nov 15, 2013
Registry last updated
May 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.